Welcome to our dedicated page for MDB Capital Holdings LLC-A SEC filings (Ticker: MDBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the story behind MDB Capital Holdings� public-venture engine often means digging through hundreds of pages that blend investment-banking footnotes with patent analytics. If you are asking, “How do I read the MDB Capital Holdings annual report 10-K simplified?� or searching for “MDB Capital Holdings insider trading Form 4 transactions,� this page is built for you.
Stock Titan pairs every fresh 10-K, 10-Q, 8-K and proxy statement with AI-powered summaries that explain, in plain language, where underwriting fees show up, how the technology-development arm is funded, and which patents moved. Our platform delivers real-time Form 4 insider transactions, so you can track executive stock moves the moment they hit EDGAR. Need the latest “MDB Capital Holdings quarterly earnings report 10-Q filing� or want “MDB Capital Holdings 8-K material events explained�? One click surfaces key numbers, material agreements, and patent-portfolio milestones without combing line by line.
Every filing type connects directly to what drives MDBH’s value: 10-K segment notes reveal broker-dealer revenue versus licensing income; 10-Q cash-flow tables expose runway for new deep-tech launches; Form 4 data highlights when principals buy ahead of a spin-out; the proxy statement details executive compensation tied to successful early IPOs. Whether you’re screening “MDB Capital Holdings executive stock transactions Form 4,� comparing fee trends quarter-over-quarter, or simply “understanding MDB Capital Holdings SEC documents with AI,� Stock Titan keeps you ahead with concise analysis, historical archives, and instant alerts.
MDB Capital Holdings, LLC (Ticker: MDBH) filed a Form 4 for insider Christopher A. Marlett, the company’s co-founder, director, and 10% owner. The filing discloses three open-market purchases of Class A common stock executed on 24-26 June 2025.
- 24 Jun 2025: 20 shares purchased at an average price of $4.46 (multiple trades between $4.35-$4.50).
- 25 Jun 2025: 2 shares purchased at $4.50.
- 26 Jun 2025: 22 shares purchased at $4.50.
The total of 44 shares acquired increases Marlett’s indirect holdings—held as custodian for a minor—to 144,279 shares. All transactions were coded “P� (open-market purchases); no derivatives were reported. Ownership remains classified as indirect (“I�) and custodial (“CUST�).
No Rule 10b5-1 trading plan is indicated, and the filing does not reference any accompanying derivative activity or larger strategic transaction. The purchases represent a 0.03 % increase in Marlett’s disclosed position and do not materially alter overall share structure, but insider buying—however small—can be interpreted as a vote of confidence. Given the limited volume and dollar value (� $200), the market impact is expected to be minimal.
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) filed a Current Report on Form 8-K disclosing the formal voting results from its 16 June 2025 Annual Meeting of Shareholders.
- Election of directors: All six nominees—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins and Dina Katabi—were re-elected, each receiving roughly 1.32�1.34 million votes FOR versus 63�73 thousand AGAINST; 743,285 broker non-votes were recorded.
- Auditor ratification: Ernst & Young LLP was confirmed for fiscal 2025 with 2,072,684 FOR, 57,547 AGAINST and 147 ABSTAIN.
- Say-on-pay (advisory): Executive compensation passed (1,312,697 FOR; 78,221 AGAINST; 6,203 ABSTAIN).
- Say-on-pay frequency: Shareholders favored an annual vote (827,809 one-year vs. 562,965 three-year).
- Adjournment authority: The option to adjourn, if necessary, also passed (2,036,703 FOR; 84,719 AGAINST; 18,984 ABSTAIN).
The filing is procedural, reinforces existing governance structures and contains no new financial, operational or strategic disclosures likely to affect the company’s near-term outlook.
MDB Capital Holdings, LLC (MDBH) � Form 4 insider transaction
On 18 June 2025, co-founder, director, officer and 10 % owner Christopher A. Marlett reported an open-market purchase (Code P) of 635 Class A common shares at a weighted-average price of $4.04 per share (individual trades ranged from $4.00 to $4.06). The shares are held indirectly as custodian for a minor. Following the trade, Marlett’s indirect beneficial ownership increased to 142,670 shares. No derivative securities were involved and no dispositions were reported.
The filing is a routine Section 16 disclosure; the dollar value of the purchase is approximately $2,560 and represents less than 1 % of Marlett’s reported holdings.
FAQ
What is the current stock price of MDB Capital Holdings LLC-A (MDBH)?
What is the market cap of MDB Capital Holdings LLC-A (MDBH)?
What is MDB Capital Holdings LLC-A's core business?
How does the company generate revenue?
What are the main operational segments of MDB Capital?
How does MDB Capital support early-stage technology companies?
What role does intellectual property play in MDB Capital’s business model?
How is MDB Capital different from traditional venture capital firms?
Who are the likely beneficiaries of MDB Capital's services?
What is the significance of the company being a registered broker-dealer?
